Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mycophenolate mofetil for difficult-to-treat rheumatoid arthritis
ChiCTR2400085240Phase 2Not yet recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of mycophenolate mofetil in rheumatoid arthritis (RA) (2 arms), sponsored by Peking University People's Hospital. Primary endpoint: ACR20 response rate at 24 weeks. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
mycophenolate mofetil
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on ChiCTR2400085240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400085240.